Ирландия - английский - HPRA (Health Products Regulatory Authority)

ethypharm - hydromorphone hydrochloride - solution for injection/infusion - 20 milligram(s)/millilitre - natural opium alkaloids; hydromorphone

Ирландия - английский - HPRA (Health Products Regulatory Authority)

ethypharm - hydromorphone hydrochloride - solution for injection/infusion - 50 milligram(s)/millilitre - natural opium alkaloids; hydromorphone

Ирландия - английский - HPRA (Health Products Regulatory Authority)

martindale pharmaceuticals ltd - hydromorphone hydrochloride - solution for injection and concentrate for infusion - 20 milligram(s)/millilitre - natural opium alkaloids; hydromorphone

Ирландия - английский - HPRA (Health Products Regulatory Authority)

martindale pharmaceuticals ltd - hydromorphone hydrochloride - solution for injection and concentrate for infusion - 50 milligram(s)/millilitre - natural opium alkaloids; hydromorphone

Соединенные Штаты - английский - NLM (National Library of Medicine)

fresenius kabi usa, llc - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride 1 mg in 1 ml - dilaudid injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. limitations of use: because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1)] , reserve dilaudid injection for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expected to be tolerated - have not provided adequate analgesia, or are not expected to provide adequate analgesia dilaudid injection is contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.2)]  - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings and precautions (5.2)]  - known or suspected gastrointestinal obstruction, including paralytic ileus [see warnings and precautions (5.9)]  - hypersensitivity to hydr

Соединенные Штаты - английский - NLM (National Library of Medicine)

mckesson rxpak inc - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride 4 mg - dilaudid oral solution and dilaudid tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.2)] , reserve dilaudid oral solution and dilaudid tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expectedto be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia dilaudid oral solution and dilaudid tablets are contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.6)] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings and precautions (5.6)] - known or suspected gastrointestinal obstruction, including

Австралия - английский - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - hydromorphone hydrochloride, quantity: 50 mg/ml - injection, concentrated - excipient ingredients: water for injections; sodium citrate dihydrate; sodium chloride; hydrochloric acid; sodium hydroxide; citric acid - dilaudid-hp injection is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - hydromorphone hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections; sodium citrate dihydrate; sodium chloride; hydrochloric acid; sodium hydroxide; citric acid - dilaudid-hp injection is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - hydromorphone hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: water for injections; sodium citrate dihydrate; sodium chloride; hydrochloric acid; sodium hydroxide; citric acid - dilaudid injection is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - hydromorphone hydrochloride, quantity: 4 mg - tablet, modified release - excipient ingredients: polyethylene oxide; povidone; magnesium stearate; butylated hydroxytoluene; sodium chloride; iron oxide black; cellulose acetate; hypromellose; macrogol 3350; iron oxide yellow; lactose; titanium dioxide; macrogol 400; iron oxide red; propylene glycol; isopropyl alcohol; purified water - jurnista is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. jurnista is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. jurnista is not indicated as an as-needed (prn) analgesia. not for use in opioid na?ve patients.